Remember Me
Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:

OpenAIRE is about to release its new face with lots of new content and services.
During September, you may notice downtime in services, while some functionalities (e.g. user registration, login, validation, claiming) will be temporarily disabled.
We apologize for the inconvenience, please stay tuned!
For further information please contact helpdesk[at]openaire.eu

fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Bulley, Catherine; Gaal, Susanne; Coutts, Fiona; Blyth, Christine; Jack, Wilma; Chetty, Udi; Barber, Matthew; Tan, Chee-Wee (2013)
Publisher: Hindawi Publishing Corporation
Journal: BioMed Research International
Languages: English
Types: Article
Subjects: R, Research Article, Medicine, Article Subject

Classified by OpenAIRE into

mesheuropmc: body regions
This study aimed to investigate lymphedema prevalence using three different measurement/diagnostic criterion combinations and explore the relationship between lymphedema and quality of life for each, to provide evaluation of rehabilitation. Cross-sectional data from 617 women attending review appointments after completing surgery, chemotherapy, and radiotherapy included the Morbidity Screening Tool (MST; criterion: yes to lymphedema); Lymphedema and Breast Cancer Questionnaire (LBCQ; criterion: yes to heaviness and/or swelling); percentage limb volume difference (perometer: %LVD; criterion: 10%+ difference); and the Functional Assessment of Cancer Therapy breast cancer-specific quality of life tool (FACT B+4). Perometry measurements were conducted in a clinic room. Between 341 and 577 participants provided sufficient data for each analysis, with mean age varying from 60 to 62 (SD 9.95-10.03) and median months after treatment from 49 to 51. Lymphedema prevalence varied from 26.2% for perometry %LVD to 20.5% for the MST and 23.9% for the LBCQ; differences were not significant. Limits of agreement analysis between %LVD and the subjective measures showed little consistency, while moderate consistency resulted between the subjective measures. Quality of life differed significantly for women with and without lymphedema only when subjective measurements were used. Results suggest that subjective and objective tools investigate different aspects of lymphedema. © 2013 Catherine Bulley et al.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • [1] J. M. Armer, M. E. Radina, D. Porock, and S. D. Culbertson, “Predicting breast cancer-related lymphedema using selfreported symptoms,” Nursing Research, vol. 52, no. 6, pp. 370- 379, 2003.
    • [2] P. A. Morgan, P. J. Franks, and C. J. Mofatt, “Health-related quality of life with lymphoedema: a review of the literature,” International Wound Journal, vol. 2, no. 1, pp. 38-62, 2005.
    • [3] Lymphoedema Framework, Best Practice for the Management of Lymphoedema. International Consensus, MEP Ltd, London, UK, 2006.
    • [4] P. T. Truong, I. A. Olivotto, T. J. Whelan, and M. Levine, “Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy,” CMAJ, vol. 170, no. 8, pp. 1263-1273, 2004.
    • [5] R. Ga¨rtner, M.-B. Jensen, L. Kronborg, M. Ewertz, H. Kehlet, and N. Kroman, “Self-reported arm-lymphedema and functional impairment aeftr breast cancer treatment-a nationwide study of prevalence and associated factors,” Breast, vol. 19, no. 6, pp. 506-515, 2010.
    • [6] T. S. Lee, S. L. Kilbreath, K. M. Refshauge, R. D. Herbert, and J. M. Beith, “Prognosis of the upper limb following surgery and radiation for breast cancer,” Breast Cancer Research and Treatment, vol. 110, no. 1, pp. 19-37, 2008.
    • [7] J. Armer, M. R. Fu, J. M. Wainstock, E. Zagar, and L. K. Jacobs, “Lymphedema following breast cancer treatment, including sentinel lymph node biopsy,” Lymphology, vol. 37, no. 2, pp. 73- 91, 2004.
    • [8] S. A. McLaughlin, M. J. Wright, K. T. Morris et al., “Prevalence of lymphedema in women with breast cancer 5 years aeftr sentinel lymph node biopsy or axillary dissection: patient perceptions and precautionary behaviors,” Journal of Clinical Oncology, vol. 26, no. 32, pp. 5220-5226, 2008.
    • [9] B. H. Cornish, B. E. Lingwood, and L. C. Ward, “Can bioimpedance spectroscopy (BIS) tell us about the form of lymphoedema?” in Proceedings of the 13th International Conference on Electrical Bioimpedance and the 8th Conference on Electrical Impedance Tomography (ICEBI '07), pp. 795-798, September 2007.
    • [10] S. Hayes, B. Cornish, and B. Newman, “Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6- month follow-up,” Breast Cancer Research and Treatment, vol. 89, no. 3, pp. 221-226, 2005.
    • [11] J. M. Armer and B. R. Stewart, “A comparison of four diagnostic criteria for lymphedema in a post-breast cancer population,” Lymphatic Research and Biology, vol. 3, no. 4, pp. 208-217, 2005.
    • [12] A. P. Sander, N. M. Hajer, K. Hemenway, and A. C. Miller, “Upper-extremity volume measurements in women with lymphedema: a comparison of measurements obtained via water displacement with geometrically determined volume,” Physical ehTrapy , vol. 82, no. 12, pp. 1201-1212, 2002.
    • [13] J. R. Karges, B. E. Mark, S. J. Stikeleather, and T. W. Worrell, “Concurrent validity of upper-extremity volume estimates: comparison of calculated volume derived from girth measurements and water displacement volume,” Physical eThrapy , vol. 83, no. 2, pp. 134-145, 2003.
    • [14] R. L. oThmas-MacLean, T. Hack, W. Kwan, A. Towers, B. Miedema, and A. Tilley, “Arm morbidity and disability aeftr breast cancer: new directions for care,” Oncology Nursing Forum, vol. 35, no. 1, pp. 65-71, 2008.
    • [15] J. Armer, B. Stewart, and R. Shook, “30-month post-breast cancer treatment lymphoedema,” Journal of Lymphoedema, vol. 4, pp. 14-18, 2009.
    • [16] V. Velanovich and W. Szymanski, “Quality of life of breast cancer patients with lymphedema,” American Journal of Surgery, vol. 177, no. 3, pp. 184-188, 1999.
    • [17] S. S. Mak, K. F. Mo, J. J. S. Suen, S. L. Chan, W. L. Ma, and W. Yeo, “Lymphedema and quality of life in Chinese women aeftr treatment for breast cancer,” European Journal of Oncology Nursing, vol. 13, no. 2, pp. 110-115, 2009.
    • [18] S. M. Beaulac, L. A. McNair, T. E. Scott, W. W. LaMorte, and M. T. Kavanah, “Lymphedema and quality of life in survivors of early-stage breast cancer,” Archives of Surgery, vol. 137, no. 11, pp. 1253-1257, 2002.
    • [19] K. Webster, D. Cella, and K. Yost, “eTh Functional Assessment of Chronic Illness eThrapy (FACIT) Measurement System: Properties, applications, and interpretation,” Health and Quality of Life Outcomes, vol. 1, article 79, 2003.
    • [20] M. J. Brady, D. F. Cella, F. Mo et al., “Reliability and validity of the functional assessment of cancer therapy-breast quality-oflife instrument,” Journal of Clinical Oncology, vol. 15, no. 3, pp. 974-986, 1997.
    • [21] S. Coster, K. Poole, and L. J. Fallowefild, “The validation of a quality of life scale to assess the impact of arm morbidity in breast cancer patients post-operatively,” Breast Cancer Research and Treatment, vol. 68, no. 3, pp. 273-282, 2001.
    • [22] T. Deltombe, J. Jamart, S. Recloux et al., “Reliability and limits of agreement of circumferential, water displacement, and optoelectronic volumetry in the measurement of upper limb lymphedema,” Lymphology, vol. 40, no. 1, pp. 26-34, 2007.
    • [23] S. A. Czerniec, L. C. Ward, K. M. Refshauge et al., “Assessment of breast cancer-related arm lymphedemacomparison of physical measurement methods and self-report,” Cancer Investigation, vol. 28, no. 1, pp. 54-62, 2010.
    • [24] J. S. Pallant, SPSS Survival Manual, Open University Press, Maidenhead, UK, 4th edition, 2010.
    • [25] D. G. Altman and J. M. Bland, “Diagnostic tests 1: sensitivity and specicfiity,” British Medical Journal, vol. 308, no. 6943, p. 1552, 1994.
    • [26] K. L. Bland, R. Perczyk, W. Du et al., “Can a practicing surgeon detect early lymphedema reliably?” American Journal of Surgery, vol. 186, no. 5, pp. 509-513, 2003.
    • [27] G. Q. Della Rovere, I. Ahmad, P. Singh, S. Ashley, I. R. Daniels, and P. Mortimer, “An audit of the incidence of arm lymphoedema aeftr prophylactic level I/II axillary dissection without division of the pectoralis minor muscle,” Annals of the Royal College of Surgeons of England, vol. 85, no. 3, pp. 158-161, 2003.
    • [28] J. M. Armer and M. R. Fu, “Age diefrences in post-breast cancer lymphedema signs and symptoms,” Cancer Nursing, vol. 28, no. 3, pp. 200-207, 2005.
    • [29] International Society of Lymphology, “eTh diagnosis and treatment of peripheral lymphoedema: consensus document,” Lymphology, vol. 36, no. 36, pp. 84-91, 2003.
  • No related research data.
  • No similar publications.
Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok